- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
FY/Q4 2013 Investor Conference Call
Friday, February 28, 2014
Start at approx. 2:30 p.m. CET (1:30 p.m. UTC)
Fiscal 2013:
Bayer continues successful course in anniversary year
Dynamic development in the Life Science businesses, MaterialScience below expectations / Outstanding growth for recently launched pharmaceutical products - estimate of combined peak annual sales potential for the five products increased to at least EUR 7.5 billion / Group sales EUR 40,157 million (plus 1.0 percent; Fx & portfolio adj.: plus 5.1 percent) / EBIT advanced by 25.6 percent to EUR 4,934 million / EBITDA before special items up by 1.5 percent to EUR 8,401 million / Net income increased 32.7 percent to EUR 3,189 million / Core earnings per share up 5.8 percent to EUR 5.61 / Forecast for 2014: further growth in sales and earnings more
MP3 Audio Recording (presentation and discussion)
You can also play the audio recording on your mobile device.
| Presentation charts | Download PDF collect (478 KB) |
| Annual Report 2013 | Download PDF collect (7 MB) |
| Q4 2013 Analyst and Investor Briefing | Download PDF collect (535 KB) |
| Transcript | Download PDF collect (160 KB) |
| FY/Q4 2013 All in One Package for Investors and Analysts All documents in one ZIP file | Download ZIP collect (8 MB) |